Prevalence of HCV among patients with HIV in Iran: A systematic review and meta-analysis

Q3 Medicine

Vacunas Pub Date : 2024-01-01 DOI:10.1016/j.vacun.2023.08.003

Maedeh Hajizadeh , Maryam Moradi Binabaj , Arezoo Asadi , Milad Abdi , Abolfazl Shakiba , Masoumeh Beig , Mohsen Heidary , Mohammad Sholeh

{"title":"Prevalence of HCV among patients with HIV in Iran: A systematic review and meta-analysis","authors":"Maedeh Hajizadeh , Maryam Moradi Binabaj , Arezoo Asadi , Milad Abdi , Abolfazl Shakiba , Masoumeh Beig , Mohsen Heidary , Mohammad Sholeh","doi":"10.1016/j.vacun.2023.08.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p><span>Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections are major </span>public health issues worldwide. The present study aimed to estimate the prevalence of HCV among patients with HIV in Iran and evaluate the demographic and behavioral factors associated with a heterogeneity of results.</p></div><div><h3>Methods</h3><p><span>MEDLINE (via PubMed), Web of Science, SCOPUS, Google Scholar, Embase, and 2 Persian databases, including Scientific Information Database (SID) and Magiran, were used for a systematic search from January 1, 2005 to February 26, 2022. Data were analyzed according to country, publication time, enrolment time, number of patients, gender, mean age, HIV/HCV diagnosis method, and HIV/HCV </span>treatment. The analysis was carried out using R and the metafor package.</p></div><div><h3>Results</h3><p>We found that 60.94 (95% CI 54.59–67.11) HIV-infected people in Iran were co-infected with HCV. The greatest burden of this co-infection was in the Hamedan 86.67 (62.12, 96.26), Kashan 85.71 (75.03, 92.30), followed by the Kerman 73.94(66.75, 80.04). The lowest prevalence of HBV-HCV co-infection was observed in Kermanshah at 11.91 (9.98, 13.98).</p></div><div><h3>Conclusion</h3><p><span>HBV-HCV co-infection is a challenging and important medical condition because of its variable clinical manifestations, increased risk of cirrhosis and HCC, and unpredictable treatment response. Due to the heterogeneous distribution pattern of HBV–HCV infection in Iran, continuous prevention and control measurements and the implementation of further </span>epidemiologic studies are necessary.</p></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vacunas","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1576988723000687","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections are major public health issues worldwide. The present study aimed to estimate the prevalence of HCV among patients with HIV in Iran and evaluate the demographic and behavioral factors associated with a heterogeneity of results.

Methods

MEDLINE (via PubMed), Web of Science, SCOPUS, Google Scholar, Embase, and 2 Persian databases, including Scientific Information Database (SID) and Magiran, were used for a systematic search from January 1, 2005 to February 26, 2022. Data were analyzed according to country, publication time, enrolment time, number of patients, gender, mean age, HIV/HCV diagnosis method, and HIV/HCV treatment. The analysis was carried out using R and the metafor package.

Results

We found that 60.94 (95% CI 54.59–67.11) HIV-infected people in Iran were co-infected with HCV. The greatest burden of this co-infection was in the Hamedan 86.67 (62.12, 96.26), Kashan 85.71 (75.03, 92.30), followed by the Kerman 73.94(66.75, 80.04). The lowest prevalence of HBV-HCV co-infection was observed in Kermanshah at 11.91 (9.98, 13.98).

Conclusion

HBV-HCV co-infection is a challenging and important medical condition because of its variable clinical manifestations, increased risk of cirrhosis and HCC, and unpredictable treatment response. Due to the heterogeneous distribution pattern of HBV–HCV infection in Iran, continuous prevention and control measurements and the implementation of further epidemiologic studies are necessary.

查看原文本刊更多论文

伊朗艾滋病毒感染者中的丙型肝炎病毒流行率：系统回顾与荟萃分析

背景人类免疫缺陷病毒（HIV）和丙型肝炎病毒（HCV）感染是全球主要的公共卫生问题。本研究旨在估算伊朗 HIV 感染者中的 HCV 感染率，并评估与结果异质性相关的人口和行为因素。方法：系统检索了 2005 年 1 月 1 日至 2022 年 2 月 26 日期间的 MedLINE（通过 PubMed）、Web of Science、SCOPUS、Google Scholar、Embase 和 2 个波斯语数据库，包括科学信息数据库 (SID) 和 Magiran。根据国家、发表时间、入选时间、患者人数、性别、平均年龄、HIV/HCV 诊断方法和 HIV/HCV 治疗方法对数据进行了分析。结果我们发现，伊朗有 60.94（95% CI 54.59-67.11）名 HIV 感染者合并感染了 HCV。哈马丹86.67 (62.12, 96.26)、卡尚85.71 (75.03, 92.30)和克尔曼73.94 (66.75, 80.04)的合并感染率最高。结论 HBV-HCV 合并感染是一种具有挑战性的重要病症，因为其临床表现多变，肝硬化和 HCC 风险增加，治疗反应难以预测。由于 HBV-HCV 感染在伊朗的分布模式各不相同，因此有必要采取持续的预防和控制措施，并开展进一步的流行病学研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vacunas Medicine-Infectious Diseases

CiteScore

3.90

自引率

0.00%

发文量

138

审稿时长

62 days

期刊介绍： Sin duda una de las mejores publicaciones para conocer los avances en el campo de las vacunaciones preventivas, tanto en el ámbito de la investigación básica como aplicada y en la evaluación de programas de vacunaciones. Su alta calidad y utilidad la ha llevado a estar indexada en los prestigiosos índices IME y SCOPUS.